The CMA’s full text decision in the long-running Hydrocortisone case, originally initiated in 2016 and in which the CMA imposed record fines, is now published and it shows a slight rethink of the CMA’s approach to excessive pricing in the pharma sector. The definition of excessive pricing as an abuse of dominance under competition law remains largely that outlined in the United Brands case from the 1970s, i.e. that the price bore “no reasonable relation to the economic value of the product”, which is assessed through a two-limb test of demonstrating that the difference between the cost incurred and the price charged was excessive (excessiveness limb) and the price was unfair either in itself
Share on
|
|
The UK Competition Authority publishes its decision to fine manufacturers of Hydrocortisone tablets £260 million for excessive pricing relying on a "Cost+" model (Auden Mckenzie / Actavis)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
